AU2020275208B2 - Formulation of delgocitinib in the form of a cream - Google Patents

Formulation of delgocitinib in the form of a cream

Info

Publication number
AU2020275208B2
AU2020275208B2 AU2020275208A AU2020275208A AU2020275208B2 AU 2020275208 B2 AU2020275208 B2 AU 2020275208B2 AU 2020275208 A AU2020275208 A AU 2020275208A AU 2020275208 A AU2020275208 A AU 2020275208A AU 2020275208 B2 AU2020275208 B2 AU 2020275208B2
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
amount
formulation according
present
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020275208A
Other languages
English (en)
Other versions
AU2020275208A1 (en
Inventor
Helene Mortensen
Jacob Nielsen
Gitte Pommergaard PEDERSEN
Pia Klie Refer
Camilla SANDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of AU2020275208A1 publication Critical patent/AU2020275208A1/en
Application granted granted Critical
Publication of AU2020275208B2 publication Critical patent/AU2020275208B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020275208A 2019-05-15 2020-05-14 Formulation of delgocitinib in the form of a cream Active AU2020275208B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19174586 2019-05-15
EP19174586.8 2019-05-15
PCT/EP2020/063518 WO2020229622A1 (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Publications (2)

Publication Number Publication Date
AU2020275208A1 AU2020275208A1 (en) 2021-10-28
AU2020275208B2 true AU2020275208B2 (en) 2025-12-04

Family

ID=66554234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020275208A Active AU2020275208B2 (en) 2019-05-15 2020-05-14 Formulation of delgocitinib in the form of a cream

Country Status (15)

Country Link
US (2) US20220241284A1 (https=)
EP (1) EP3968997B1 (https=)
JP (2) JP7734587B2 (https=)
KR (1) KR20220008893A (https=)
CN (1) CN113825512A (https=)
AU (1) AU2020275208B2 (https=)
BR (1) BR112021022031A2 (https=)
CA (1) CA3137247A1 (https=)
IL (1) IL288011A (https=)
MX (1) MX2021012874A (https=)
SG (1) SG11202110777XA (https=)
TW (1) TWI863995B (https=)
UA (1) UA129431C2 (https=)
WO (1) WO2020229622A1 (https=)
ZA (1) ZA202107300B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia
WO2024194105A1 (en) * 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017125523A1 (en) * 2016-01-21 2017-07-27 Leo Pharma A/S Treatment of hand eczema

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8883838B2 (en) * 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
PT3297605T (pt) * 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017125523A1 (en) * 2016-01-21 2017-07-27 Leo Pharma A/S Treatment of hand eczema

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, INTERNET CITATION, 27 April 2017 (2017-04-27), pages 1 - 3, XP002779505, Retrieved from the Internet [retrieved on 20180323] *
ATSUO TANIMOTO ET AL., EXPERIMENTAL DERMATOLOGY, vol. 27, no. 1, 3 July 2017 (2017-07-03), COPENHAGEN; DK, pages 22 - 29, XP055711911, ISSN: 0906-6705, DOI: 10.1111/exd.13370 *
EMILIE S. CHAN ET AL., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 135, no. 7, 1 July 2015 (2015-07-01), NL, pages 1912 - 1915, XP055712047, ISSN: 0022-202X, DOI: 10.1038/jid.2015.107 *
H. NAKAGAWA ET AL, BRITISH JOURNAL OF DERMATOLOGY, vol. 178, no. 2, 15 January 2018 (2018-01-15), UK, pages 424 - 432, XP055712044, ISSN: 0007-0963, DOI: 10.1111/bjd.16014 *
PATRIA INACIO: "Cutaneous Lupus Erythematosus Patients May Benefit from JAK1 Inhibitors", INTERNET CITATION, 17 October 2016 (2016-10-17), pages 1, XP002779504, Retrieved from the Internet [retrieved on 20180323] *

Also Published As

Publication number Publication date
AU2020275208A1 (en) 2021-10-28
UA129431C2 (uk) 2025-04-23
JP2025114800A (ja) 2025-08-05
KR20220008893A (ko) 2022-01-21
CN113825512A (zh) 2021-12-21
EP3968997B1 (en) 2026-03-18
EP3968997A1 (en) 2022-03-23
BR112021022031A2 (pt) 2021-12-28
US20260069595A1 (en) 2026-03-12
TWI863995B (zh) 2024-12-01
WO2020229622A1 (en) 2020-11-19
CA3137247A1 (en) 2020-11-19
TW202106690A (zh) 2021-02-16
JP7734587B2 (ja) 2025-09-05
JP2022533526A (ja) 2022-07-25
SG11202110777XA (en) 2021-11-29
MX2021012874A (es) 2021-11-17
US20220241284A1 (en) 2022-08-04
IL288011A (en) 2022-01-01
ZA202107300B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP6438466B2 (ja) イベルメクチンによる丘疹膿疱性の酒さの治療
US20260069595A1 (en) Formulation of delgocitinib in the form of a cream
AU2022252766B2 (en) Treatment of hand eczema
WO2023202989A1 (en) Treatment of frontal fibrosing alopecia
TWI720022B (zh) 圓禿之新穎治療
RU2847397C2 (ru) Лечение кожной формы красной волчанки
HK40063225A (en) Treatment of cutaneous lupus erythematosus
HK40102338A (en) Treatment of hand eczema
WO2025085050A1 (en) Treatment of frontal fibrosing alopecia
HK1260652A1 (en) Use of delgocitinib for the treatment of chronic hand eczema
HK1260652B (en) Use of delgocitinib for the treatment of chronic hand eczema

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ FORMULATION OF DELGOCITINIB IN THE FORM OF A CREAM

FGA Letters patent sealed or granted (standard patent)